Browse
Prediction results retrieved after performance evaluation of WHO approved 34 primers to estimate their binding affinities for 3892 SARS-CoV-2 variants.

Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used
  
HK.24NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
HK.24NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XCFNUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
XCFNUS-CDC-N-1TCTGGTTACTGCCAGTTGAATCTG2445.832835828335R-25148.4US
XCFNUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
XCFNUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
XCFNUS-CDC-N-3GGGAGCCTTGAATACACCAAAA2245.452868128702F-22824.1US
XCFNUS-CDC-N-3TGTAGCACGATTGCAGCATTG2147.622875228732R-23779.6US
XCFNSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
XCFNSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
CH.1.1.32NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
CH.1.1.32NUS-CDC-N-1TCTGGTTACTGCCAGTTGAATCTG2445.832835828335R-21820.8US
CH.1.1.32NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-16719.1US
CH.1.1.32NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
CH.1.1.32NUS-CDC-N-3GGGAGCCTTGAATACACCAAAA2245.452868128702F-22824.1US
CH.1.1.32NUS-CDC-N-3TGTAGCACGATTGCAGCATTG2147.622875228732R-23779.6US
CH.1.1.32NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
CH.1.1.32NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XBB.1.5.109NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
XBB.1.5.109NUS-CDC-N-1TCTGGTTACTGCCAGTTGAATCTG2445.832835828335R-25148.4US
XBB.1.5.109NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
XBB.1.5.109NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
XBB.1.5.109NUS-CDC-N-3GGGAGCCTTGAATACACCAAAA2245.452868128702F-22824.1US
XBB.1.5.109NUS-CDC-N-3TGTAGCACGATTGCAGCATTG2147.622875228732R-23779.6US
XBB.1.5.109NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
XBB.1.5.109NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
FR.1.5NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
FR.1.5NUS-CDC-N-1TCTGGTTACTGCCAGTTGAATCTG2445.832835828335R-25148.4US
FR.1.5NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
FR.1.5NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
FR.1.5NUS-CDC-N-3GGGAGCCTTGAATACACCAAAA2245.452868128702F-22824.1US
FR.1.5NUS-CDC-N-3TGTAGCACGATTGCAGCATTG2147.622875228732R-23779.6US
FR.1.5NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
FR.1.5NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
JN.10NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
JN.10NUS-CDC-N-1TCTGGTTACTGCCAGTTGAATCTG2445.832835828335R-25148.4US
JN.10NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
JN.10NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
JN.10NUS-CDC-N-3GGGAGCCTTGAATACACCAAAA2245.452868128702F-22824.1US
JN.10NUS-CDC-N-3TGTAGCACGATTGCAGCATTG2147.622875228732R-23779.6US
JN.10NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
JN.10NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
HK.12NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-18526.8US
HK.12NUS-CDC-N-1TCTGGTTACTGCCAGTTGAATCTG2445.832835828335R-25148.4US
HK.12NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
HK.12NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
HK.12NUS-CDC-N-3GGGAGCCTTGAATACACCAAAA2245.452868128702F-22824.1US
HK.12NUS-CDC-N-3TGTAGCACGATTGCAGCATTG2147.622875228732R-23779.6US
HK.12NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
HK.12NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used